Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) have earned a consensus rating of “Moderate Buy” from the five ratings firms that are currently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $4.60.

Separately, HC Wainwright lowered their price objective on Karyopharm Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a research note on Friday, June 28th.

Karyopharm Therapeutics Stock Performance

KPTI stock opened at $0.87 on Thursday. The stock’s 50 day simple moving average is $1.00 and its 200 day simple moving average is $1.11. Karyopharm Therapeutics has a fifty-two week low of $0.62 and a fifty-two week high of $1.95. The company has a market cap of $108.00 million, a P/E ratio of -0.68 and a beta of 0.22.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.01. The firm had revenue of $33.13 million for the quarter, compared to analyst estimates of $35.02 million. Equities analysts predict that Karyopharm Therapeutics will post -1.24 earnings per share for the current year.

Insider Transactions at Karyopharm Therapeutics

In other news, Director Deepika Pakianathan sold 204,394 shares of the stock in a transaction that occurred on Friday, May 31st. The stock was sold at an average price of $0.95, for a total value of $194,174.30. Following the completion of the sale, the director now directly owns 14,697 shares of the company’s stock, valued at $13,962.15. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders sold a total of 1,282,955 shares of company stock valued at $1,243,470 over the last ninety days. 4.30% of the stock is currently owned by insiders.

Institutional Trading of Karyopharm Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Bleakley Financial Group LLC purchased a new stake in shares of Karyopharm Therapeutics during the fourth quarter valued at approximately $33,000. BNP Paribas Financial Markets increased its position in shares of Karyopharm Therapeutics by 6.5% during the fourth quarter. BNP Paribas Financial Markets now owns 1,769,184 shares of the company’s stock valued at $1,530,000 after acquiring an additional 108,286 shares during the last quarter. GSA Capital Partners LLP purchased a new stake in shares of Karyopharm Therapeutics during the third quarter valued at approximately $762,000. Panagora Asset Management Inc. purchased a new stake in shares of Karyopharm Therapeutics during the fourth quarter valued at approximately $197,000. Finally, Exchange Traded Concepts LLC increased its position in shares of Karyopharm Therapeutics by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 115,864 shares of the company’s stock valued at $100,000 after acquiring an additional 29,380 shares during the last quarter. 66.44% of the stock is owned by hedge funds and other institutional investors.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).